EMORY UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1836-12-10

Employees: 10K

Market Cap: -

Website: http://www.emory.edu

Clinical Trials

Healthy Homes/Healthy Families (HH/HF) Intervention in 2-1-1 Callers

Not Applicable

Completed

Conditions: Weight Change, Body

Interventions: Behavioral: Control
Behavioral: Health Homes/Healthy Families (HH/HF) Intervention

First Posted Date: 2020-05-04

Last Posted Date: 2024-02-12

Lead Sponsor: Emory University

Target Recruit Count: 512

Registration Number: NCT04373434

Locations: 🇺🇸
Emory University, Rollins School of Public Health, Atlanta, Georgia, United States

Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q System

Not Applicable

Conditions: Acute Respiratory Distress Syndrome
COVID-19

Interventions: Device: V/Q System

First Posted Date: 2020-04-30

Last Posted Date: 2024-06-21

Lead Sponsor: Emory University

Target Recruit Count: 36

Registration Number: NCT04369599

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19

Phase 1

Terminated

Conditions: Coronavirus Infection in 2019 (COVID-19)
Pneumonia
Severe Acute Respiratory Syndrome (SARS) Pneumonia

Interventions: Radiation: Low Dose Radiation Therapy

First Posted Date: 2020-04-29

Last Posted Date: 2022-03-29

Lead Sponsor: Emory University

Target Recruit Count: 47

Registration Number: NCT04366791

Locations: 🇺🇸
Emory University Hospital Midtown/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Emory Saint Joseph's Hosptial, Atlanta, Georgia, United States

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Phase 3

Withdrawn

Conditions: SARS Coronavirus 2 Infection
Chronic Obstructive Pulmonary Disease
Chronic Renal Failure
Coronary Artery Disease
Diabetes Mellitus
Cerebrovascular Accident
Malignant Neoplasm

Interventions: Other: Best Practice
Biological: Tocilizumab

First Posted Date: 2020-04-24

Last Posted Date: 2020-06-18

Lead Sponsor: Emory University

Registration Number: NCT04361552

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

Phase 2

Terminated

Conditions: Plasma Cell Myeloma
Renal Failure

Interventions: Drug: Bortezomib
Biological: Daratumumab
Drug: Dexamethasone
Drug: Lenalidomide
Drug: Thalidomide

First Posted Date: 2020-04-20

Last Posted Date: 2024-07-01

Lead Sponsor: Emory University

Target Recruit Count: 17

Registration Number: NCT04352205

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits

Phase 4

Completed

Conditions: Major Depression

Interventions: Drug: Bupropion XL
Drug: Escitalopram

First Posted Date: 2020-04-20

Last Posted Date: 2023-12-29

Lead Sponsor: Emory University

Target Recruit Count: 18

Registration Number: NCT04352101

Locations: 🇺🇸
Emory Clinic, Atlanta, Georgia, United States

Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer

Phase 1

Terminated

Conditions: Stage IA1 Lung Cancer AJCC v8
Stage IIB Lung Cancer AJCC v8
Stage IA3 Lung Cancer AJCC v8
Stage IB Lung Cancer AJCC v8
Stage II Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IA2 Lung Cancer AJCC v8
Stage IIA Lung Cancer AJCC v8
Lung Non-Small Cell Carcinoma
Stage I Lung Cancer AJCC v8

Interventions: Drug: Durvalumab
Drug: Sirolimus

First Posted Date: 2020-04-16

Last Posted Date: 2024-08-22

Lead Sponsor: Emory University

Target Recruit Count: 3

Registration Number: NCT04348292

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer

Not Applicable

Recruiting

Conditions: Small-cell Lung Cancer

Interventions: Radiation: Proton-beam Therapy for Small Cell Lung Cancer

First Posted Date: 2020-04-13

Last Posted Date: 2024-03-25

Lead Sponsor: Emory University

Target Recruit Count: 30

Registration Number: NCT04342429

Locations: 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States

Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases

Phase 3

Active, not recruiting

Conditions: Zika
Chikungunya
Aedes-borne Diseases
Dengue

Interventions: Biological: Targeted Indoor Residual Spraying (TIRS)

First Posted Date: 2020-04-13

Last Posted Date: 2024-05-14

Lead Sponsor: Emory University

Target Recruit Count: 4702

Registration Number: NCT04343521

Locations: 🇲🇽
Universidad Autonoma de Yucatan, Merida, Yucatan, Mexico

Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade

Phase 2

Recruiting

Conditions: Metastatic Non-Small Lung Cell Cancer
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8
Recurrent Non-Small Lung Cell Cancer

Interventions: Drug: Docetaxel
Biological: Pembrolizumab
Biological: Ramucirumab

First Posted Date: 2020-04-10

Last Posted Date: 2024-02-13

Lead Sponsor: Emory University

Target Recruit Count: 41

Registration Number: NCT04340882

Locations: 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸
Grady Health System, Atlanta, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy